<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132976">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02109978</url>
  </required_header>
  <id_info>
    <org_study_id>CRF117</org_study_id>
    <secondary_id>12/SW/0348</secondary_id>
    <nct_id>NCT02109978</nct_id>
  </id_info>
  <brief_title>RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes</brief_title>
  <acronym>RetroMASTER</acronym>
  <official_title>Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes:</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NIHR Exeter Clinical Research Facility</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Devon and Exeter NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NIHR Exeter Clinical Research Facility</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine extreme responders to second- and third-line Type 2 Diabetes (T2D)
      therapy using a retrospective approach and patients with slow or fast diabetes progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PILOT Phase (March 2013 - Dec 2014) Patients will be recruited initially from 2 centres,
      plus Exeter as a pre-PILOT centre.  Patients with particularly good or poor response to
      second- and third-line Type 2 diabetes treatments and patients progressing to insulin either
      particularly quickly or particularly slowly will be recruited from primary, secondary, or
      community settings.  Fasting blood and urine samples will be collected, along with standard
      biomeasures and information will be collected about medical history and prescribing history.

      All study documentation and sample materials will be sent out to sites from the coordinating
      centre.  Sites will be expected to process and freeze samples and send them to the Central
      Laboratory managed by the Chief Inspector's site where they will be analysed for genetic
      factors, glycaemic markers and other markers related to drug response.

      POST-PILOT Phase (Jan 2015- Oct 2017): Subject to feasibility, interim analysis and
      continuation of funding from Medical Research Council (MRC), this project will continue for
      another three years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Response to diabetes therapy and rate of diabetes progression</measure>
    <time_frame>Within 9 months from date of recruitment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome will be to compare the clinical characteristics of the patients who show an excellent response or poor response to specific second- and third- line classes of treatment for Type 2 diabetes; and of those patients that show rapid progression of Type 2 diabetes or slow progression of Type 2 diabetes to markedly high blood glucose despite the treatment that they require.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collection of samples for analysis of potential biomarkers</measure>
    <time_frame>within 9 months of recruitment date</time_frame>
    <safety_issue>No</safety_issue>
    <description>To collect a set of DNA, serum and urine samples to allow analysis of potential genetic and non-genetic biomarkers for drug response and diabetes progression.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Responders</arm_group_label>
    <description>Patients with Type 2 diabetes that have been taking a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors, Glitazone or insulin) for at least 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progressors</arm_group_label>
    <description>Patients with Type 2 diabetes that progressed to requiring insulin treatment ≤10 years from diagnosis or have had no requirement for insulin treatment &gt;10 years from diagnosis.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      At Visit 1 a fasting blood sample (approximately 35 mls) will be taken for DNA extraction,
      and to measure for markers of the progression of diabetes or response to diabetes medication
      and for secondary markers that may predict response. A urine sample is also collected to
      measure for biomarkers.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be identified in primary care and secondary care. The method for patient
        identification may differ between sites and could involve:

        GP Searches; Secondary Care Clinician Referral; Research Database Searches.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Generic Inclusion Criteria:

          -  Demographics: Age 18-90 inclusive

          -  Ethnicity: Reflective of local demographic

          -  Medical History: Clinical diagnosis of Type 2 diabetes

          -  Mental Capacity: Capacity to Consent

        Responders Cohort Inclusion Criteria:

          -  On Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone for &gt;
             4 months.

          -  Pre-treatment HbA1c≥ 58mmol/mol (7.5%).

        Progressors Cohort Inclusion Criteria:

          -  Type 2 diabetes (not on insulin treatment within 6 months of diagnosis)

          -  Either: requirement for insulin treatment ≤10 years from diagnosis (defined as
             insulin treatment or HbA1c ≥ 69mmol/mol (8/5%) treated with two or more non-insulin
             diabetes therapies) or: no requirement for insulin treatment &gt;10 years from diagnosis
             (defined as not on insulin treatment AND HbA1c &lt;69mmol/mol (8.5%).

        Exclusion Criteria:

          -  Age less than 18 years old and greater than 90 years old

          -  Incapacity to consent

          -  Type 1 diabetes.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew T Hattersley, FRCP, DM, BM</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Exeter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Angwin, BA; MSc</last_name>
    <phone>++44 1392 408185</phone>
    <email>c.angwin@exeter.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Hudson, BSc, PGCE</last_name>
    <phone>++44 1392 408183</phone>
    <email>m.hudson@exeter.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Exeter</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Angwin, BA, MSc</last_name>
      <phone>++44 1392 408185</phone>
      <email>c.angwin@exeter.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Hudson, BSc</last_name>
      <phone>++44 1392 408183</phone>
      <email>m.hudson@exeter.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew T Hattersley, FAMS, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oxford</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX1 2JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicky McRobert</last_name>
      <email>Nicky.Mcrobert@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Stephen Gough</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Dundee</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Smith</last_name>
      <email>nataliesmith1@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Emma Gellatly</last_name>
      <email>E.J.Z.Gellatly@dundee.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Ewan Pearson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>April 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Diabetes therapy response</keyword>
  <keyword>Diabetes progression</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
